TLX insider buying and SEC filings, explained
Telix Pharmaceuticals Ltd · CIK 2007191
Tracked: Forms 3/4/5, 8-K, NT · All filings on sec.gov
Insider activity in the last 12 months
Bought
$1.0M
Insiders who bought
2
Sold (not marked 10b5-1)
$0
Planned sales (10b5-1)
$0
Insider purchases and sales, last 12 months
| Traded | Type | What was filed | Source |
|---|---|---|---|
| Sep 7, 2026 | Purchase (code P) | Darren Charlton Smith (CFO) bought 2,071 shares at $9.66 ($20K), reported as a purchase (code P). Holdings up 17% to 13,992 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Sep 14, 2026 |
| Apr 28–29, 2026 | Purchase (code P) | Christian Behrenbruch (CEO and Director) bought 67,935 shares indirectly (by entity) between Apr 28 and Apr 29 at about $14.67 ($997K), reported as a purchase (code P). Holdings by entity up <1% to 20,742,935 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed May 6, 2026 |
1 routine transaction (such as a grant, option exercise or tax withholding) is not listed.
Cluster buys
No cluster buys in the last 12 months.
Red flags
No red flags in the last 12 months.
Key events
No key events in the last 12 months.
8-K filings, last 12 months
No 8-K filings in the last 12 months.
Red flags are objective triggers only: the item or form filed, never an opinion.
Follow TLX in the Insider Ledger app
Get the appA plain-English brief of insider purchases, 8-Ks and red flags at the companies you pick. No account needed.